| Dr Matthew R Durkin, OD | |
|
8395 Oswego Rd, Malara Eyecare And Eyewear Gallery, Baldwinsville, NY 13027-6801 | |
| (315) 622-3500 | |
| (315) 622-3522 |
| Full Name | Dr Matthew R Durkin |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 25 Years |
| Location | 8395 Oswego Rd, Baldwinsville, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417951872 | NPI | - | NPPES |
| 01960892 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | TUV006167-1 (New York) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Richard C Malara Od Pc | 7719965839 | 4 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
If the Texas Legislature is in session, there must be a fight about Medicaid going on. The health care program for the disabled, the elderly poor and the impoverished raises hackles every two years, mostly because the number in need keeps rising alongside health care costs.
The first ever patient to have undergone gene therapy for Parkinson's appears to have come through phase I without a hitch, suggesting that the therapy is safe and effective, reports Marina Murphy in Chemistry & Industry.
Progressive high-impact training improved the patellar cartilage quality of the postmenopausal women who may be at risk of osteoporosis (bone loss) as well as at risk of osteoarthritis.
› Verified 3 days ago
| Provider Name | Richard C Malara Od Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1336346550 PECOS PAC ID: 7719965839 Enrollment ID: O20040713001249 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
If the Texas Legislature is in session, there must be a fight about Medicaid going on. The health care program for the disabled, the elderly poor and the impoverished raises hackles every two years, mostly because the number in need keeps rising alongside health care costs.
The first ever patient to have undergone gene therapy for Parkinson's appears to have come through phase I without a hitch, suggesting that the therapy is safe and effective, reports Marina Murphy in Chemistry & Industry.
Progressive high-impact training improved the patellar cartilage quality of the postmenopausal women who may be at risk of osteoporosis (bone loss) as well as at risk of osteoarthritis.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew R Durkin, OD 8395 Oswego Rd, Malara Eyecare And Eyewear Gallery, Baldwinsville, NY 13027-6801 Ph: (315) 622-3500 | Dr Matthew R Durkin, OD 8395 Oswego Rd, Malara Eyecare And Eyewear Gallery, Baldwinsville, NY 13027-6801 Ph: (315) 622-3500 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
If the Texas Legislature is in session, there must be a fight about Medicaid going on. The health care program for the disabled, the elderly poor and the impoverished raises hackles every two years, mostly because the number in need keeps rising alongside health care costs.
The first ever patient to have undergone gene therapy for Parkinson's appears to have come through phase I without a hitch, suggesting that the therapy is safe and effective, reports Marina Murphy in Chemistry & Industry.
Progressive high-impact training improved the patellar cartilage quality of the postmenopausal women who may be at risk of osteoporosis (bone loss) as well as at risk of osteoarthritis.
› Verified 3 days ago
Optisight Ltd. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 52 Oswego St, Baldwinsville, NY 13027 Phone: 315-635-3904 Fax: 315-635-5525 | |
Dr. Thomas Norbert Helget, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 22 Endora Dr, Baldwinsville, NY 13027 Phone: 315-635-9679 | |
Malara Eyecare & Eyewear Gallery Optometrist Medicare: Medicare Enrolled Practice Location: 8395 Oswego Rd, Suite 7c, Baldwinsville, NY 13027 Phone: 315-622-3500 Fax: 315-622-3522 | |
Dr. Richard Christian Malara, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 8395 Oswego Rd, Kimbrook Village Square, Baldwinsville, NY 13027 Phone: 315-622-3500 Fax: 315-622-3522 | |
Dr. Mark H Meyers, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 6291 Mourning Dove, Baldwinsville, NY 13027 Phone: 315-303-4811 |